Evidence map›Paper›PMID 36869646›Full record

ArticleCancer2023

Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.

Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M Bui, Charuta C Palsuledesai, Meenakshi Malhotra and 6 more

3 registry-linked trialsOpen access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06566404 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma Eligible for Lymph Node Sentinel Biopsy (CORRESPOND): an Observational Prospective Study.

TypeobservationalSponsorEuropean Institute of OncologyRan2024 to 2028Enrolled200ConditionsMelanoma
NCT06710093 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma

Typeobservational_patient_registrySponsorRoyal Marsden NHS Foundation TrustRan2025 to 2029Enrolled100ConditionsMetastatic Melanoma
NCT07689812 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors

TypeinterventionalSponsorNatera, Inc.Ran2026 to 2034Enrolled920ConditionsNSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLCArmsSignatera Genome ultra-sensitive ctDNA blood test
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. Article
  7. Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.American journal of clinical dermatology · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Advances in Cancer Immunotherapy for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  12. Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Zeynep ErogluDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0002-2307-7030
Shifra KrinshpunNatera, Inc, Austin, Texas, USA.
Ekaterina KalashnikovaNatera, Inc, Austin, Texas, USA.
Sumedha SudhamanNatera, Inc, Austin, Texas, USA.
Turkan Ozturk TopcuDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Matt NicholsDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Justin MartinDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Katherine M BuiDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Charuta C PalsuledesaiNatera, Inc, Austin, Texas, USA.ORCID 0000-0002-3850-260X
Meenakshi MalhotraNatera, Inc, Austin, Texas, USA.
Perry OlshanNatera, Inc, Austin, Texas, USA.
Joseph MarkowitzDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Nikhil I KhushalaniDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Ahmad A TarhiniDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Jane L MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Alexey AleshinNatera, Inc, Austin, Texas, USA.
Moffitt Cancer Center · USNatera (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have substantially improved overall survival in patients with advanced melanoma; however, the lack of biomarkers to monitor treatment response and relapse remains an important clinical challenge. Thus, a reliable biomarker is needed that can risk-stratify patients for disease recurrence and predict response to treatment.

methodsA retrospective analysis using a personalized, tumor-informed circulating tumor DNA (ctDNA) assay on prospectively collected plasma samples (n = 555) from 69 patients with advanced melanoma was performed. Patients were divided into three cohorts: cohort A (N = 30), stage III patients receiving adjuvant ICI/observation; cohort B (N = 29), unresectable stage III/IV patients receiving ICI therapy; and cohort C (N = 10), stage III/IV patients on surveillance after planned completion of ICI therapy for metastatic disease.

resultsIn cohort A, compared to molecular residual disease (MRD)-negative patients, MRD-positivity was associated with significantly shorter distant metastasis-free survival (DMFS; hazard ratio [HR], 10.77; p = .01). Increasing ctDNA levels from the post-surgical or pre-treatment time point to after 6 weeks of ICI were predictive of shorter DMFS in cohort A (HR, 34.54; p < .0001) and shorter progression-free survival (PFS) in cohort B (HR, 22; p = .006). In cohort C, all ctDNA-negative patients remained progression-free for a median follow-up of 14.67 months, whereas ctDNA-positive patients experienced disease progression.

conclusionPersonalized and tumor-informed longitudinal ctDNA monitoring is a valuable prognostic and predictive tool that may be used throughout the clinical course of patients with advanced melanoma.

Indexed as

Circulating Tumor DNAMelanomaBiomarkers, TumorDNA, NeoplasmHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesBiomarkers, TumorCirculating Tumor DNADNA, Neoplasmadvanced melanomacirculating tumor DNA (ctDNA)immune checkpoint inhibitors (ICI)molecular residual disease (MRD)treatment monitoring

Identifiers

PMID36869646
OpenAlexW4323050295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.